Fate Therapeutics Inc (NASDAQ: FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Take a look at the 1-year chart of Fate (NASDAQ: FATE) below with added notations:

1-year chart of Fate (NASDAQ: FATE)

FATE had been trading overall sideways for most of 2018, while stalling at the $14 level (green) each time it was approached. That level was also FATE’s 52-week high resistance barrier, and now that the stock has broken above it, traders might look to enter a position during the current pullback down to the $14 area.

The Tale of the Tape: FATE broke its 52-week resistance at $14. The possible long position on the stock would be on a pullback down to that level with a stop placed under it. A break back below $14 could negate the forecast for a move higher.

Before making any trading decision, decide which side of the trade you believe gives you the highest probability of success. Do you prefer the short side of the market, long side, or do you want to be in the market at all? If you haven’t thought about it, review the overall indices themselves. For example, take a look at the S&P 500. Is it trending higher or lower? Has it recently broken through a key resistance or support level? Making these decisions ahead of time will help you decide which side of the trade you believe gives you the best opportunities.

No matter what your strategy or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!

Good luck!

Christian Tharp, CMT